Sino Biopharmaceutical Ltd. has agreed to acquire nearly all remaining shares of LaNova Medicines Ltd., a Chinese biotech with a pipeline of eight clinical-stage candidates including antibody-drug conjugates and bispecific antibodies. The deal values LaNova at up to $950.9 million, reflecting Sino’s confidence in LaNova’s oncology portfolio, which includes drugs licensed by Merck and AstraZeneca. The acquisition highlights rapid growth and innovation within China’s biotech sector and its expanding footprint in global pharmaceutical development.